Why the Acronym PCOS Should Have Been Preserved: A Constructive Response to the Lancet PMOS Proposal

MD FRCOG MSc

The purpose of a disease name is not only to improve scientific accuracy. A successful name should:

The most important question is: will changing the acronym from PCOS to PMOS significantly improve diagnosis, treatment, or public understanding?

In my view, the answer is probably not.

The article states that:

This demonstrates that changing the acronym carries substantial logistical and educational costs. It is also worth noting that the consensus process has not fully disclosed whether the 84% who favored a new name were primarily clinicians, researchers, or patients — a distinction that matters considerably when evaluating whether the change serves those most affected by the condition.

The scientific case for renaming is strong, and it deserves full acknowledgment. PCOS is a misnomer in at least three meaningful ways: polycystic ovaries are neither a defining feature nor a requirement for diagnosis; the condition is fundamentally endocrine and metabolic in origin, not primarily ovarian; and the word “syndrome” undersells what is increasingly understood as a lifelong systemic disorder.

These are not cosmetic complaints. Clinicians report that patients fixate on the ovarian framing, leading some to believe they are “cured” after successful fertility treatment, or to underestimate their long-term cardiovascular and metabolic risk. A name that obscures the disease’s true nature can genuinely impede care.

Despite this, PCOS has become one of the most recognized disorders in women’s health — not because of its name, but in spite of it. The field has built global awareness campaigns, international guidelines, major research funding, patient advocacy organizations, and social media communities under an admittedly imperfect acronym. This suggests the barrier to progress has never been the letters themselves, but the education and clinical training surrounding them.

The question, then, is not whether the name should evolve — it should — but whether changing the acronym is the most efficient lever for achieving that evolution.

Over decades, PCOS has become a globally recognized term. Patients search for “PCOS.” Support groups are named around PCOS. Clinical guidelines and textbooks use PCOS. Research literature is indexed under PCOS.

This recognition represents a powerful educational and advocacy asset. Discarding the acronym risks patient confusion, search engine fragmentation, temporary loss of awareness, and disruption of established advocacy efforts.

One underappreciated consequence of abandoning the PCOS acronym is its effect on established professional and patient organizations whose identities are built around the letters “PC.”

Organizations such as the PCOS Society, PCOS Challenge, and PCOS Awareness Association have spent years — in some cases decades — building brand recognition, donor relationships, membership bases, and public trust under names anchored to those two letters. Under the proposed transition, these organizations face a difficult choice: rename and absorb the reputational and financial cost of rebranding, or retain their existing names and risk appearing misaligned with the new official terminology.

Neither option is good. Renaming fractures continuity. Not renaming creates confusion.

This is not a trivial administrative burden. Rebranding a nonprofit involves legal filings, updated materials, donor re-education, website migration, and — most critically — rebuilt search visibility. For smaller advocacy organizations operating on limited budgets, this cost could be genuinely prohibitive.

The Lancet proposal’s 3-year transition plan does not appear to adequately account for this institutional dimension. Scientific bodies and hospital systems can update guidelines. Patient advocacy organizations cannot simply absorb a rebrand without real harm to the communities they serve.

This is precisely the kind of collateral disruption that preserving the PCOS acronym would have avoided entirely.

A more effective solution would have been to retain the acronym while redefining what the letters stand for. My preferred terminology is:

Polyendocrine Cardiometabolic Ovarian Syndrome (PCOS)

This name:

• Preserves the globally recognized acronym
• Reflects endocrine dysfunction
• Highlights cardiometabolic risk
• Retains the ovarian component
• Avoids the misleading reference to “cysts”

The addition of cardiometabolic is particularly important because long-term cardiovascular and metabolic risks are central to this condition.

The Lancet article emphasizes increased risks of insulin resistance, dyslipidemia, hypertension, type 2 diabetes, cardiovascular disease, stroke, and myocardial infarction. Given these consequences, explicitly recognizing cardiometabolic risk in the name itself would better communicate the disorder’s lifelong health implications — not just to patients, but to non-specialist clinicians who may otherwise underestimate the condition’s systemic reach.

The article itself recommends “evolutionary rebranding” rather than revolutionary change. Preserving PCOS while updating its meaning is exactly that: scientifically updated, publicly familiar, easier to implement, less disruptive, and more likely to achieve rapid acceptance.

The practical test is straightforward. Will a young woman who has heard of PCOS better understand her condition if the acronym becomes PMOS? Most likely, she will first ask: “What is PMOS?” Changing the acronym creates a new educational challenge rather than leveraging decades of established recognition.

The proposal to rename PCOS reflects important scientific progress and deserves appreciation. The underlying condition is poorly served by its current name, and the impulse to correct that is right.

However, the ultimate purpose of nomenclature is practical impact. If the goal is to improve awareness, diagnosis, and long-term care, then preserving the globally recognized acronym while redefining its meaning would have been the more strategic choice — one that honors both the science and the infrastructure built around it.

Polyendocrine Cardiometabolic Ovarian Syndrome (PCOS)

This option maintains decades of global recognition, accurately reflects multisystem disease, highlights cardiometabolic risk, avoids misleading terminology, and minimizes confusion and implementation burden — including for the patient organizations that have carried this cause forward.

A name should clarify science, but it should also preserve the hard-earned public awareness already built around a condition. The institutional cost of abandoning a familiar acronym falls heaviest not on guideline committees, but on the patients and advocates who built communities around it.

Sometimes the most effective reform is not to discard a familiar identity, but to redefine it.

PCOS deserved modernization — not replacement.